Trial · NCT00358579
Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest
NCT00358579, Phase 3, Completed, Singapore General Hospital; results first posted 2011-08-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest. Trials, record NCT00358579. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00358579
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing Vasopressin and Adrenaline in Patients With Cardiac Arrest
- NCT number
- NCT00358579
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 727 participants, actual
- Lead sponsor
- Singapore General Hospital
- Conditions
- Cardiac Arrest
- Interventions
- Adrenaline, Vasopressin
- First posted
- 2006-08-01
- Last updated
- 2017-03-17
- Results first posted
- 2011-08-09
- Limitations and caveats
As the study was conducted over a relatively long period, results may be affected by secular trends.Variations in post-resuscitation care can affect survival to discharge status and variations between institutions are difficult to account for.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Survival to Hospital Discharge. | at 30 days post arrest | Survival to hospital discharge is defined as the patient leaving the hospital alive or survival to 30 days post cardiac arrest,whichever came first. This therefore measures the number of participants who was discharged alive or survived to 30 days post cardiac arrest, whichever came first. |
| Secondary | Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | at 30 days post arrest | Neurological status is assessed by the Glasgow-Pittsburgh outcome categories, to evaluate quality of life after successful resuscitation. Good neurological status is defined as cerebral performance categories(CPC)/overall performance categories(OPC):1 and 2.CPC/OPC 1 indicates good cerebral \& overall performance. CPC/OPC 2 indicates moderate cerebral \& overall disability. CPC/OPC 3 indicates severe cerebral \& overall disability. CPC/OPC 4 indicates coma, vegetative state. CPC/OPC 5 indicates brain dead/death. |
| Secondary | Neurological Status at 1 Year. | at 1 year post arrest | Neurological status is assessed by the Glasgow-Pittsburgh outcome categories, to evaluate quality of life after successful resuscitation. Good neurological status is defined as cerebral performance categories(CPC)/overall performance categories(OPC): 1 and 2. CPC/OPC 1 indicates good cerebral \& overall performance. CPC/OPC 2 indicates moderate cerebral \& overall disability. CPC/OPC 3 indicates severe cerebral \& overall disability. CPC/OPC 4 indicates coma, vegetative state. CPC/OPC 5 indicates brain dead/death. |
| Secondary | Return of Spontaneous Circulation. | during resuscitation | Return of spontaneous circulation is defined as the presence of any palpable pulse detected by manual palpation of a major artery. This is measured as number of participants who had return of spontaneous circulation during resuscitation. |
| Secondary | Survival to Admission. | No specific time frame. Survival to admission refers to sustained return of spontaneous circulation until admission and transfer of care to Intensive Care Units /wards | Survival to admission is defined as the presence of pulse on admission to hospital (discharged from Emergency Department and admitted to Intensive Care Units /wards). This measures the number of participants with pulse and who were admitted to hospital. |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Survival to Hospital Discharge. | at 30 days post arrest | Participants | NUMBER | |
| SECONDARY | Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | at 30 days post arrest | Participants | NUMBER | |
| SECONDARY | Neurological Status at 1 Year. | at 1 year post arrest | Participants | NUMBER | |
| SECONDARY | Return of Spontaneous Circulation. | during resuscitation | Participants | NUMBER | |
| SECONDARY | Survival to Admission. | No specific time frame. Survival to admission refers to sustained return of spontaneous circulation until admission and transfer of care to Intensive Care Units /wards | Participants | NUMBER |
Source ClinicalTrials.gov
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Survival to Hospital Discharge. | Adrenaline | 8 | Participants | ||
| Survival to Hospital Discharge. | Vasopressin | 11 | Participants | ||
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Adrenaline | Cerebral Performance Categories 1 | 5 | Participants | |
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Vasopressin | Cerebral Performance Categories 1 | 4 | Participants | |
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Adrenaline | Cerebral Performance Categories 2 | 0 | Participants | |
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Vasopressin | Cerebral Performance Categories 2 | 1 | Participants | |
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Adrenaline | Overall Performance Categories 1 | 2 | Participants | |
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Vasopressin | Overall Performance Categories 1 | 5 | Participants | |
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Adrenaline | Overall Performance Categories 2 | 3 | Participants | |
| Neurological Status on Discharge or at 30 Days Post Arrest, if Not Discharged. | Vasopressin | Overall Performance Categories 2 | 0 | Participants |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Adrenaline | 353 | |
| Overall Study | STARTED | Vasopressin | 374 | |
| Overall Study | COMPLETED | Adrenaline | 353 | |
| Overall Study | COMPLETED | Vasopressin | 374 | |
| Overall Study | NOT COMPLETED | Adrenaline | 0 | |
| Overall Study | NOT COMPLETED | Vasopressin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Adrenaline | ||
| Total, all-cause mortality | Vasopressin | ||
| Total, other adverse events | Adrenaline | 0 | 0 |
| Total, other adverse events | Vasopressin | 0 | 0 |
| Total, serious adverse events | Adrenaline | 0 | 0 |
| Total, serious adverse events | Vasopressin | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22353644 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Adrenaline vs Vasopressin: Survival to Admission. | Trial comparisons |
| Adrenaline vs Vasopressin: Return of Spontaneous Circulation. | Trial comparisons |
| Adrenaline vs Vasopressin: Survival to Hospital Discharge. | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00358579
GET https://conductscience.org/api/trials/v1/NCT00358579/results?page=2